Skip to main content
  • ORBITA Reboot Giving PCI Another Shot to Beat Sham

    Rasha Al-Lamee, MD, on the sequel to the controversial stent vs sham trial

    With ORBITA-2, percutaneous coronary intervention (PCI) gets a second chance to prove it's better than placebo for symptom relief in stable angina after the first randomized sham-controlled trial of stenting came out negative.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details